Key facts
- Jaderberg said he does not want the shift to AI-designed drugs to take 20 or 50 years to happen passively.
- Isomorphic Labs is a spinout of Alphabet's Google DeepMind, founded in 2021, and builds on the AlphaFold protein model.
- The company's internal programs focus on cancer, immune system disorders and inflammation-related conditions.
- Jaderberg said Isomorphic remains in preclinical trials with Eli Lilly and Novartis.
Isomorphic Labs president Max Jaderberg said at Bloomberg Tech London on November 2, 2026, that artificial intelligence will design every medicine in the future, and that the only uncertainty is how quickly that happens. He said he did not want the shift to take 20 or 50 years to arrive passively.
Isomorphic Labs is a spinout of Alphabet's Google DeepMind, founded in 2021, and builds on the AlphaFold protein-folding model. The company develops AI models for its own drug programs and for partner biopharma companies, with internal work focused on cancer, immune system disorders and inflammation-related conditions.
Jaderberg said Isomorphic remains in preclinical trials with Eli Lilly and Novartis. Bloomberg reported in October 2026 that the company entered talks for a funding round that could value it at $40 billion or more; Isomorphic has not disclosed its valuation since announcing fresh funding in May 2026. The company has raised approximately $2.7 billion from backers including Alphabet and Thrive Capital, according to the report.